Good start to 2016 for Bayer as 1st-qtr earnings leap nearly 16%

26 April 2016
bayer-location2-big

Germany’s largest pharma company Bayer (BAYN: DE) saw its shares rise 1.9% to 111.75 euros in early trading, after it reported first-quarter 2016 financial results, with strong newer pharma product sales and earnings that exceeded forecasts.

The company said profit before interest, taxes, depreciation and amortization (EBITDA), adjusted for one-off items, increased 15.7% to 3.4 billion euros ($3.83 billion), beating average market expectations of 3.07 billion euros. Net profit for the period was 1.51 billion euros, up 13.5% compared with 1.33 billion during the same period last year, besting analysts' forecasts of 1.45 billion euros, according to a recent poll conducted by The Wall Street Journal.

On a reported basis, first-quarter group sales rose a modest 0.5% to 11.94 billion euros, boosted by strong sales of the company's recently launched prescription medicines. Sales of the Bayer group increased by 3.2% to 1.94 billion after adjusting for currency and portfolio changes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical